Showing 4831-4840 of 6036 results for "".
- Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedulehttps://modernod.com/news/iveric-bio-completes-patient-enrollment-of-gather2-pivotal-clinical-trial-of-zimura-ahead-of-schedule-2/2479422/Iveric bio announced the early completion of patient enrollment of GATHER2, the company’s second pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company expects topline GATHE
- Ocular Therapeutix Announces First Patient Dosed in US-Based Phase 1 Trial of OTX-TKI for Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-us-based-phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-wet-amd/2479421/Ocular Therapeutix announced that it has dosed the first patient in the United States phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (AMD). “We are very excited to have recently begu
- FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet AMD and DMEhttps://modernod.com/news/fda-accepts-application-for-genentechs-faricimab-for-the-treatment-of-wet-amd-and-dme/2479419/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic r
- Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedulehttps://modernod.com/news/iveric-bio-completes-patient-enrollment-of-gather2-pivotal-clinical-trial-of-zimura-ahead-of-schedule/2479414/Iveric bio announced the early completion of patient enrollment of GATHER2, the company’s second pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company expects topline GATHE
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- BVI Announces Collaboration With BeyeOnics Visionhttps://modernod.com/news/bvi-announces-collaboration-with-beyeonics-vision/2479411/BVI announces a collaboration with Israel-based BeyeOnics Vision, a maker of in head-mounted display, digital data, and imaging processing. BeyeOnics Vision has been developing BeyeOnics 1, which the company describes as the first and only ophthalmic digital imaging system replacing the op
- LumiThera: Data Show Valeda Treatments Improve Vision and Retinal Function in Dry AMD patientshttps://modernod.com/news/lumithera-data-show-valeda-treatments-improve-vision-and-retinal-function-in-dry-amd-patients/2479408/LumiThera, a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, announced the final topline data from the ELECTROLIGHT pilot study in intermediate dry AMD patients. A total of 23 eyes from 15 subjects with dry AMD were enro
- Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edemahttps://modernod.com/news/adverum-provides-update-on-advm-022-and-the-infinity-trial-in-patients-with-diabetic-macular-edema/2479404/Adverum Biotechnologies provided an update on the ADVM-022 development program following a thorough review of data available from the INFINITY clinical trial in patients with diabetic macular edema (DME) and the OPTIC clinical trial in patients with wet age-related macular degeneration (AMD). The
- Johnson & Johnson Vision Launches Veritas Vision Systemhttps://modernod.com/news/johnson-johnson-vision-introduces-veritas-vision-system-with-features-to-address-key-unmet-needs-in-cataract-surgery/2479401/Johnson & Johnson Vision announced the global availability of the Veritas Vision System, a next-generation phacoemulsification system designed to address three critical areas: patient safety, surgeon efficiency and comfort. The company will offer live demos of the new system in a wet lab at t
- ArcScan Signs Agreement for $11.15 Million Preferred Series B Investment with Shanghai Haohai Biological Technologyhttps://modernod.com/news/arcscan-signs-agreement-for-11-15-million-preferred-series-b-investment-with-shanghai-haohai-biological-technology/2479394/ArcScaan announced the execution of a Stock Purchase Agreement with Shanghai Haohai Biological Technology that will result in a $11.15 million Preferred Series B investment into ArcScan. Haohai is a leading Chinese ophthalmology and medical aesthetics company headquartered in Shanghai, and is pub